已收录 272983 条政策
 政策提纲
  • 暂无提纲
An investigation into tetraspanin CD151 as novel prognostic markers in poor outcome endometrial cancer
[摘要] Background: Type II endometrial carcinoma, sarcoma and carcinosarcoma account for 10% of uterine malignancies but 50% of recurrences. Survival at recurrence is poor and better prognostic markers are needed to guide therapy. The prognostic significance of the novel markers clusterin and tetraspanin CD151 were evaluated in a cohort of poor outcome endometrial malignancies, along with oestrogen receptor, progesterone receptor, p53 and human epidermal growth factor receptor 2. Immunohistochemistry profiles and survival outcome between grade 3 endometroid cancers and type 2 cancers were compared. Material and Methods: Tissue microarrays constructed from 156 poor outcome uterine malignancies, tested with immunohistochemistry and staining were correlated with clinicopathological, mortality and survival data. Results: Expression of CD151 was significantly higher in uterine papillary serous and clear cell carcinoma (USPC+CC) compared to grade 3 endometrioid carcinoma, sarcoma or carcinosarcoma. All other markers were not prognostic for survival. Except for CD151, there was no significant difference in marker positivity, age, stage or survival between G3 EEC and UPSC+CC. Conclusion: CD151 is a novel marker in type 2 cancers that may guide therapeutic decisions. These data also suggest that grade 3 EEC is better characterised as a type II endometrial cancer and may benefit from similar treatment.
[发布日期]  [发布机构] University:University of Birmingham;Department:Institute of Cancer Studies
[效力级别]  [学科分类] 
[关键词] R Medicine;RC Internal medicine;RC0254 Neoplasms. Tumors. Oncology (including Cancer) [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文